1613231-49-4
Chemical Structure
RALA peptide
- CAS 番号: 1613231-49-4
- Formula:C144H248N54O35S
- Molecular Weight:3327.92
SMILES: O=C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CS)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)N
Biological Activity: RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization)[1][2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RALA peptide | 98.38% | RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.85
HY-P2530KALA -
Similarity Score 0.80
HY-P5423GALA -
Similarity Score 0.72
HY-P6306CS-6253 -
Similarity Score 0.72
HY-P5594Dermaseptin-S1 -
Similarity Score 0.71
HY-P4800Osteostatin (human) -
Similarity Score 0.71
HY-P1297CRF(6-33)(human) -
Similarity Score 0.71
HY-P10443ppTG20 -
Similarity Score 0.70
HY-P4818Human PTH-(1-31) amide -
Similarity Score 0.70
HY-P4817Human PTH-(1-31) -
Explore the MedChemAI to find more analogs
References
- [1]. Massey AS, et al. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. Mol Pharm. 2016 Apr 4;13(4):1217-28. [Content Brief]
- [2]. O'Doherty M, et al. Improving the Intercellular Uptake and Osteogenic Potency of Calcium Phosphate via Nanocomplexation with the RALA Peptide. Nanomaterials (Basel). 2020 Dec 7;10(12):2442 [Content Brief]
- [3]. Sathy BN, et al. RALA complexed α-TCP nanoparticle delivery to mesenchymal stem cells induces bone formation in tissue engineered constructs in vitro and in vivo. J Mater Chem B. 2017 Mar 7;5(9):1753-1764. [Content Brief]
